Therapeutic Drug Monitoring Market by Product (Consumables, Equipment-Immunoassay Analyzers, Chromatography & MS Detectors, Clinical Chemistry Analyzers), Technology, Class of drugs, End user and Region - Global Forecast to 2026
[298 Pages Report] The global therapeutic drug monitoring market is projected to reach USD 2.7 billion by 2026 from USD 1.6 billion in 2020, at a CAGR of 9.4% during the forecast period. The growth of this market is majorly driven by the rising number of organ transplant procedures, the use of TDM across various therapeutic fields, the increasing preference for precision medicine, a growing focus on R&D related to TDM, and technological advancements in immunoassay instruments. However, the need for high capital investments and the reluctance of small hospitals to offer TDM services may restrain the growth of this market.
To know about the assumptions considered for the study, Request for Free Sample Report
COVID -19 IMPACT ON therapeutic drug monitoring market.
Globally, Globally, the COVID-19 outbreak has impacted every aspect of the pharmaceutical, diagnostics, and medical industry, including the therapeutic drug monitoring market.
Data from the Scottish Biologic Therapeutic Drug Monitoring (TDM) service shows a drop in TDM testing since pandemic onset. For instance, in April 2020, a 75.6% reduction in adalimumab testing and a 36.2% reduction in infliximab testing was noticed, mainly due to a large number of cancellations of outpatient. Likewise, it is also believed that disruption to normal patterns of care and disease monitoring of patients on biologics could increase the threat of disease and adverse clinical reactions.
Research associations and other medical bodies are making various attempts to conduct clinical trials to develop a suitable anti-COVID drug, which is anticipated to fuel the growth of the TDM market. Moreover, the Pharmacology group - AC43 of the National Agency for Research on AIDS and Viral Hepatitis and the Therapeutic Drug Monitoring Group of the French Society of Pharmacology and Therapeutics proposed, at the end of March 2020, that a TDM evaluation be performed 48 hours after the start of treatment to check the early attainment of an adequate residual concentration.
Additionally, closed manufacturing facilities disrupted supply chains and reduced recruitments; however, in the COVID-19 pandemic recovery phase 2021, restoring clinical trials will continue to be a challenge because of restricted access at trial sites. Hence further delay in the clinical trials will impact the growth of the overall therapeutic drug monitoring market in 2021.
In conclusion, the exposure of new variants of COVID will increase the high demand for new clinical trials to identify and evaluate the effectiveness of certain drugs against COVID-19 during the forecast period.
Global Therapeutic Drug Monitoring Dynamics
DRIVER: Increasing preference for precision medicine
Precision medicine is an evolving approach for disease treatment and prevention that considers individual variability in genes, environments, and lifestyles. Precision medicine involves selecting drugs wholly tailored to a patient based on disease condition and history. Although this practice is expanding into all disease areas, oncology has seen the most progress.
Currently, cancer patients are being provided treatment through combination drugs, based on studies conducted on the patient’s parameters such as systems biology, analysis of the tumor, and gene expression data in the absence and presence of pharmacological perturbation. This approach, which is currently being tested in various settings, aims to revolutionize pharmacotherapy in oncology and other disease areas. TDM can be of immense value to advance this novel way of treating patients.
Studies also reveal that drug therapies for major diseases benefit only 30–50% of patients, while nearly 7% of hospitalized patients experience adverse drug reactions. The personalization of drug therapy explores the patients’ response to drugs to maximize effects while minimizing the risk of adverse reactions due to toxicity or sub-therapeutic dosing. TDM has been proposed to adjust the drug dosage individually based on the pharmacokinetic profile obtained. At present, over 20 drugs are routinely monitored. The promising benefits offered by precision medicine are expected to propel the demand for TDM in this application.
OPPORTUNITY: Increasing adoption in the treatment of autoimmune diseases
Anti-TNF-alpha biologics are an effective treatment for autoimmune diseases, such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). With the increasing healthcare costs and patent expiries, the number of R&D activities focusing on the development of biosimilars has increased over the last few years. The launch of biosimilars in the market is increasing the need for a better understanding of potential differences in biosimilar immunogenicity and their safety and efficacy profiles compared to their precursors. For instance, TNF-alpha blockers, such as infliximab and adalimumab, can both trigger immunogenicity responses; researchers have hypothesized that their biosimilars drugs (CT-P13) may also promote immunogenicity. Therefore, it is vital to develop methods for the TDM of biosimilar drugs for autoimmune diseases to ensure effective patient care.
CHALLENGE: Operational barriers faced in conducting TDM tests
Clinical laboratories across major markets are still evolving. As a result, technicians face operational challenges in ensuring effective sample procurement, storage, and transportation, especially while adopting novel technologies such as chemiluminescence immunoassays, HPLC, and multiplex flow immunoassays (MFI). Laboratory space also needs to be reconfigured to meet the requirements of conducting specific immunoassay tests for pathogen detection to avoid cross-contamination and ensure efficient time management. The need to maintain and operate advanced immunoassay instruments, particularly those capable of handling a single sample type, is highly expensive.
Due to the rapid mutation of microbes and the increasing outbreak of epidemics, clinical laboratories need to adopt innovative technologies capable of rapid sample diagnosis. However, a shortage of skilled laboratory technicians to operate advanced immunoassay diagnostic products limits their overall adoption, particularly in emerging markets. Also, the reluctance to move from manual operations toward automation is another major challenge for market growth. This is because many providers find it difficult to transition to IT-based approaches from manual or traditional approaches and may not prefer to make the shift at all.
Consumables in the product segment to witness the highest growth as well as the largest share of the Therapeutic Drug Monitoring during the forecast period.
Based on the product, the Therapeutic Drug Monitoring market is segmented into Consumables, Equipment-Immunoassay Analyzers, Chromatography & MS Detectors, Clinical Chemistry Analyzers. The Consumables segment is projected to grow at the highest CAGR during the forecast period. The major factors contributing to the growth of this market are the requirement of repeat purchase of kits and reagents, coupled with the increasing number of immunoassay tests being performed across the globe.
North America accounted for the largest share of the Therapeutic Drug Monitoring market in 2021
Based on the region, the Therapeutic Drug Monitoring market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2021, North America accounted for the largest share of the Therapeutic Drug Monitoring market. Growth in this market can be attributed to increasing per capita healthcare expenditure and the presence of technologically advanced healthcare infrastructure. Moreover, the focus of the region has shifted from performing simple TDM assays to holistic testing to understand the gaps between prescribing the correct dosage of the drug and achieving the desired clinical outcome.
To know about the assumptions considered for the study, download the pdf brochure
Key Market Players
Some of the major players operating in this market are Abbott (US), F. Hoffmann-La Roche (Switzerland), Siemens Healthineers AG. (Germany), Thermo Fisher Scientific (US), Danaher Corporation (US), and Bio-Rad Laboratories (US). In 2020, Abbott (US held the leading position in the market. The company has a strong geographic presence across North America, Europe, and Asia Pacific. Thermo Fisher Scientific (US), held the second position in the peripheral vascular devices market in 2021.
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
|
Report Metric |
Details |
|
Market Size Available for Years |
2016–2026 |
|
Base Year Considered |
2020 |
|
Forecast Period |
2021–2026 |
|
Forecast Units |
Value (USD) |
|
Segments Covered |
Product, Technology, Class of drugs, End user and Region |
|
Geographies Covered |
North America (US, Canada), Europe (Germany, France, UK, Spain, Italy and RoE), APAC (China, India, Japan, and the RoAPAC), and Rest of the World (Latin America- and Middle East & Africa) |
|
Companies Covered |
Abbott (US), Thermo Fisher Scientific (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Bio-Rad Laboratories (US), bioMérieux SA (France), Theradiag SA (France), Grifols S.A. (Spain), Exagen Inc. (US), R-Biopharm AG (Germany), ApDia Group (Belgium), UTAK (US), Randox Laboratories Ltd. (Ireland), ARK Diagnostics, Inc. (US). BioTeZ Berlin-Buch GmbH (Germany), Eagle Biosciences, Inc. (US), Jasem Laboratory Systems and Solutions (Turkey), Aalto Scientific, Ltd. (US), Immundiagnostik AG (Germany), Sekisui Medical Co. Ltd. (Japan), DiaSystem Scandinavia AB (Sweden), Cambridge Life Sciences Limited (UK), Chromsystems Instruments & Chemicals GmbH (Germany), and BÜHLMANN Laboratories (Switzerland). |
This research report categorizes the Therapeutic Drug Monitoring market into the following segments and subsegments:
Product Split |
|
|
Technology Split |
|
|
Class of drug Split |
|
|
End user Split |
|
Recent Developments:
- In 2021, Thermo Fisher Scientific (US) partnered with Mindray on Clinical Chemistry Analyzers for use with Drugs of Abuse Immunoassays.
- In 2020, F. Hoffmann-La Roche (Switzerland) announced that, New diagnostics will be built featuring of labs, biotech production and office workspace in of South Africa To strengthen its offerings in its diagnostics segment
Frequently Asked Questions (FAQ):
What is the projected market value of the global Therapeutic Drug Monitoring market?
The global market of Therapeutic Drug Monitoring is projected to reach USD 2.7 billion by 2026.
What is the estimated growth rate (CAGR) of the global Therapeutic Drug Monitoring market for the next five years?
The global Therapeutic Drug Monitoring market is projected to grow at a Compound Annual Growth Rate (CAGR) of 9.4% from 2021 to 2026.
Who are the major players offering Therapeutic Drug Monitorings in the market?
Abbott (US), Thermo Fisher Scientific (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Bio-Rad Laboratories (US), bioMérieux SA (France), Theradiag SA (France), Grifols S.A. (Spain), Exagen Inc. (US), R-Biopharm AG (Germany), ApDia Group (Belgium), UTAK (US), Randox Laboratories Ltd. (Ireland), ARK Diagnostics, Inc. (US). .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 40)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS COVERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 MARKET STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 45)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 4 REVENUE SHARE ANALYSIS ILLUSTRATION: THERMO FISHER SCIENTIFIC
FIGURE 5 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
2.2.1 GROWTH FORECAST
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 7 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 ASSUMPTIONS FOR THE STUDY
2.6 INDICATORS AND ASSUMPTIONS AND THEIR IMPACT ON THE STUDY
2.6.1 COVID-19-SPECIFIC ASSUMPTIONS
2.7 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT
2.8 COVID-19 HEALTH ASSESSMENT
2.9 COVID-19 ECONOMIC ASSESSMENT
2.10 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
3 EXECUTIVE SUMMARY (Page No. - 61)
FIGURE 11 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
FIGURE 12 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
FIGURE 13 THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021 VS. 2026 (USD MILLION)
FIGURE 14 THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 15 GEOGRAPHIC SNAPSHOT OF THE GLOBAL THERAPEUTIC DRUG MONITORING MARKET
4 PREMIUM INSIGHTS (Page No. - 65)
4.1 THERAPEUTIC DRUG MONITORING MARKET OVERVIEW
FIGURE 16 RISING PREFERENCE FOR PRECISION MEDICINE TO DRIVE THE TDM MARKET
4.2 THERAPEUTIC DRUG MONITORING MARKET, BY TYPE
FIGURE 17 CONSUMABLE PRODUCTS TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2021
4.3 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG
FIGURE 18 ANTIEPILEPTIC DRUGS WILL DOMINATE THE ASIA PACIFIC MARKET IN 2021-2026
4.4 GEOGRAPHIC SNAPSHOT OF THE THERAPEUTIC DRUG MONITORING MARKET
FIGURE 19 CHINA TO REGISTER THE HIGHEST CAGR OVER THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 68)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 20 THERAPEUTIC DRUG MONITORING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Importance of TDM in organ transplant procedures
FIGURE 21 NUMBER OF DECEASED DONORS AND TRANSPLANTS IN THE UK (APRIL 1, 2017–MARCH 31, 2021)
5.2.1.2 Use of TDM across various therapeutic fields
TABLE 2 CLASSES OF DRUGS THAT REQUIRE MONITORING
5.2.1.3 Increasing preference for precision medicine
5.2.1.4 Growing focus on R&D related to TDM
FIGURE 22 NUMBER OF RESEARCH PUBLICATIONS ON THERAPEUTIC DRUG MONITORING (2015–2020)
5.2.1.5 Technological advancements
5.2.2 RESTRAINTS
5.2.2.1 Requirement of high capital investments
5.2.2.2 Reluctance of small hospitals to offer TDM services
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing adoption in the treatment of autoimmune diseases
5.2.4 CHALLENGES
5.2.4.1 Alternatives to conventional TDM
5.2.4.2 Operational barriers faced in conducting TDM tests
5.3 COVID-19 IMPACT ON THE THERAPEUTIC DRUG MONITORING MARKET
5.4 RANGES/SCENARIOS
5.4.1 THERAPEUTIC DRUG MONITORING MARKET
FIGURE 23 PESSIMISTIC SCENARIO
FIGURE 24 OPTIMISTIC SCENARIO
FIGURE 25 REALISTIC SCENARIO
5.5 VALUE CHAIN ANALYSIS
FIGURE 26 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 27 DIRECT DISTRIBUTION—THE PREFERRED STRATEGY FOR PROMINENT COMPANIES
5.7 PORTER’S FIVE FORCES ANALYSIS
5.7.1 THREAT OF NEW ENTRANTS
5.7.2 INTENSITY OF COMPETITIVE RIVALRY
5.7.3 BARGAINING POWER OF BUYERS
5.7.4 BARGAINING POWER OF SUPPLIERS
5.7.5 THREAT OF SUBSTITUTES
5.8 REGULATORY LANDSCAPE
5.9 PATENT ANALYSIS
5.10 PRICING ANALYSIS
TABLE 3 PRICE RANGE FOR THERAPEUTIC DRUG MONITORING
5.11 TRADE ANALYSIS
TABLE 4 IMPORT DATA FOR INSTRUMENTS AND APPLIANCES USED IN PHYSICAL AND CHEMICAL ANALYSIS, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 5 EXPORT DATA FOR INSTRUMENTS AND APPLIANCES USED IN PHYSICAL AND CHEMICAL ANALYSIS, BY COUNTRY, BY COUNTRY, 2016–2020 (USD MILLION)
5.12 ECOSYSTEM ANALYSIS
5.12.1 ROLE IN ECOSYSTEM
FIGURE 28 KEY PLAYERS IN THE THERAPEUTIC DRUG MONITORING
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.13.1 REVENUE SHIFT AND REVENUE POCKETS FOR THERAPEUTIC DRUG MONITORING MARKET
5.13.2 REVENUE SHIFT FOR THERAPEUTIC DRUG MONITORING
6 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT (Page No. - 87)
6.1 INTRODUCTION
TABLE 6 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2020 (USD MILLION)
TABLE 7 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021–2026 (USD MILLION)
6.2 CONSUMABLES
6.2.1 REPEAT PURCHASE AND HIGH USAGE OF CONSUMABLES DRIVE MARKET GROWTH
TABLE 8 THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 9 THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY REGION, 2021–2026 (USD MILLION)
6.3 EQUIPMENT
TABLE 10 DRUGS MONITORED USING ANALYTICAL EQUIPMENT
TABLE 11 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 12 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 13 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 14 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY REGION, 2021–2026 (USD MILLION)
6.3.1 IMMUNOASSAY ANALYZERS
6.3.1.1 The high efficiency of immunoassay analyzers has ensured end-user demand
TABLE 15 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY REGION, 2016–2020 (USD MILLION)
TABLE 16 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY REGION, 2021–2026 (USD MILLION)
6.3.2 CHROMATOGRAPHY & MS DETECTORS
6.3.2.1 Technological advancements have propelled the growth of the segment
TABLE 17 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & MS DETECTORS, BY REGION, 2016–2020 (USD MILLION)
TABLE 18 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & MS DETECTORS, BY REGION, 2021–2026 (USD MILLION)
6.3.3 CLINICAL CHEMISTRY ANALYZERS
6.3.3.1 Automation to raise preference for clinical chemistry analyzers
TABLE 19 THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2016–2020 (USD MILLION)
TABLE 20 THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2021–2026 (USD MILLION)
6.4 IMPACT OF COVID-19 ON THE TDM MARKET, BY PRODUCT
7 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY (Page No. - 95)
7.1 INTRODUCTION
TABLE 21 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION)
TABLE 22 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
7.2 IMMUNOASSAYS
TABLE 23 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 24 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 25 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 26 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY REGION, 2021–2026 (USD MILLION)
7.2.1 CHEMILUMINESCENCE IMMUNOASSAYS
7.2.1.1 Rapid detection time and good specificity support the growth of the segment
TABLE 27 CLIA SYSTEMS AVAILABLE IN THE MARKET
TABLE 28 LIST OF COMPOUNDS ANALYZED BY CHEMILUMINESCENCE IMMUNOASSAY
TABLE 29 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 30 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY REGION, 2021–2026 (USD MILLION)
7.2.2 FLUORESCENCE IMMUNOASSAYS
7.2.2.1 High operability and better sensitivity of FIAs to drive market growth
TABLE 31 LIST FOR COMPOUNDS ANALYZED BY FLUORESCENCE POLARIZATION IMMUNOASSAYS
TABLE 32 FLUORESCENCE IMMUNOASSAYS MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 33 FLUORESCENCE IMMUNOASSAYS MARKET, BY REGION, 2021–2026 (USD MILLION)
7.2.3 COLORIMETRIC IMMUNOASSAYS
7.2.3.1 Demand for colorimetric immunoassays to decline due to the rising preference for advanced equipment
TABLE 34 COLORIMETRIC IMMUNOASSAYS MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 35 COLORIMETRIC IMMUNOASSAYS MARKET, BY REGION, 2021–2026 (USD MILLION)
7.2.4 RADIOIMMUNOASSAYS
7.2.4.1 High sensitivity in drug detection applications supports the market for radioimmunoassays
TABLE 36 LIST OF COMPOUNDS ANALYZED BY RADIOIMMUNOASSAYS
TABLE 37 RADIOIMMUNOASSAYS MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 38 RADIOIMMUNOASSAYS MARKET, BY REGION, 2021–2026 (USD MILLION)
7.2.5 OTHER IMMUNOASSAYS
TABLE 39 OTHER IMMUNOASSAYS MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 40 OTHER IMMUNOASSAYS MARKET, BY REGION, 2021–2026 (USD MILLION)
7.3 CHROMATOGRAPHY-MS
TABLE 41 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION)
TABLE 42 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION)
7.3.1 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY
7.3.1.1 High accuracy supports the demand for LC-MS
TABLE 43 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 44 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2021–2026 (USD MILLION)
7.3.2 GAS CHROMATOGRAPHY-MASS SPECTROMETRY
7.3.2.1 Drawbacks of GC-MS challenge market growth
TABLE 45 GAS CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 46 GAS CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2021–2026 (USD MILLION)
8 THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG (Page No. - 110)
8.1 INTRODUCTION
TABLE 47 THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION)
TABLE 48 THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION)
8.2 ANTIEPILEPTIC DRUGS
8.2.1 HIGH COMPLEXITY AND HETEROGENEITY OF EPILEPSY TO DRIVE THE GROWTH OF THE SEGMENT
TABLE 49 LIMITATIONS OF TDM OF NEWER ANTIEPILEPTIC DRUGS
TABLE 50 ANTIEPILEPTIC DRUG MONITORING MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 51 ANTIEPILEPTIC DRUG MONITORING MARKET, BY REGION, 2021–2026 (USD MILLION)
8.3 ANTIARRHYTHMIC DRUGS
8.3.1 INCREASING INCIDENCE OF HEART DISORDERS TO SUPPORT SEGMENT GROWTH
TABLE 52 ANTIARRHYTHMIC DRUG MONITORING MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 53 ANTIARRHYTHMIC DRUG MONITORING MARKET, BY REGION, 2021–2026 (USD MILLION)
8.4 IMMUNOSUPPRESSANT DRUGS
8.4.1 IMMUNOSUPPRESSANT DEMAND HAS RISEN DUE TO AN INCREASE IN ORGAN TRANSPLANTATION PROCEDURES
TABLE 54 IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 55 IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY REGION, 2021–2026 (USD MILLION)
8.5 ANTIBIOTIC DRUGS
8.5.1 TECHNOLOGICAL ADVANCEMENTS TO PROPEL THE DEMAND FOR ANTIBIOTIC DRUG MONITORING
TABLE 56 ANTIBIOTIC DRUG MONITORING MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 57 ANTIBIOTIC DRUG MONITORING MARKET, BY REGION, 2021–2026 (USD MILLION)
8.6 BRONCHODILATOR DRUGS
8.6.1 INCREASING PREVALENCE OF RESPIRATORY DISEASES WILL ENSURE DEMAND FOR BRONCHODILATOR DRUG MONITORING
TABLE 58 BRONCHODILATOR DRUG MONITORING MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 59 BRONCHODILATOR DRUG MONITORING MARKET, BY REGION, 2021–2026 (USD MILLION)
8.7 PSYCHOACTIVE DRUGS
8.7.1 RISING CASES OF MENTAL ILLNESS TO DRIVE MARKET GROWTH
TABLE 60 PSYCHOACTIVE DRUG MONITORING MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 61 PSYCHOACTIVE DRUG MONITORING MARKET, BY REGION, 2021–2026 (USD MILLION)
8.8 OTHER DRUGS
TABLE 62 OTHER DRUG MONITORING MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 63 OTHER DRUG MONITORING MARKET, BY REGION, 2021–2026 (USD MILLION)
8.9 IMPACT OF COVID-19 ON THE TDM MARKET, BY CLASS OF DRUG
9 THERAPEUTIC DRUG MONITORING MARKET, BY END USER (Page No. - 121)
9.1 INTRODUCTION
TABLE 64 THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2020 (USD MILLION)
TABLE 65 THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2021–2026 (USD MILLION)
9.2 HOSPITAL LABORATORIES
9.2.1 HOSPITAL LABS HOLD THE LARGEST SHARE OF THE END-USER MARKET
TABLE 66 THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2016–2020 (USD MILLION)
TABLE 67 THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2021–2026 (USD MILLION)
9.3 COMMERCIAL & PRIVATE LABORATORIES
9.3.1 EXTENSIVE TEST MENUS OF COMMERCIAL & PRIVATE LABS SUPPORT DEMAND FOR THEIR SERVICES
TABLE 68 THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY REGION, 2016–2020 (USD MILLION)
TABLE 69 THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY REGION, 2021–2026 (USD MILLION)
9.4 OTHER END USERS
TABLE 70 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, BY REGION, 2016–2020 (USD MILLION)
TABLE 71 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, BY REGION, 2021–2026 (USD MILLION)
9.5 IMPACT OF COVID-19 ON THE TDM MARKET, BY END USER
10 THERAPEUTIC DRUG MONITORING MARKET, BY REGION (Page No. - 126)
10.1 INTRODUCTION
TABLE 72 THERAPEUTIC DRUG MONITORING MARKET, BY REGION, 2016–2020 (USD MILLION)
TABLE 73 THERAPEUTIC DRUG MONITORING MARKET, BY REGION, 2021–2026 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 29 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARK ET SNAPSHOT
TABLE 74 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 75 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
TABLE 76 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2020 (USD MILLION)
TABLE 77 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021–2026 (USD MILLION)
TABLE 78 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 79 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 80 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION)
TABLE 81 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 82 NORTH AMERICA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 83 NORTH AMERICA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 84 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION)
TABLE 85 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION)
TABLE 86 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION)
TABLE 87 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION)
TABLE 88 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2020 (USD MILLION)
TABLE 89 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2021–2026 (USD MILLION)
10.2.1 US
10.2.1.1 Awareness regarding precision medicine to propel the TDM market in the US
TABLE 90 NUMBER OF TESTS COVERED BY MEDICARE FOR EACH DRUG CLASS
TABLE 91 US: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2020 (USD MILLION)
TABLE 92 US: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021–2026 (USD MILLION)
TABLE 93 US: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION)
TABLE 94 US: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 95 US: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 96 US: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 97 US: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION)
TABLE 98 US: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION)
TABLE 99 US: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION)
TABLE 100 US: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION)
TABLE 101 US: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2020 (USD MILLION)
TABLE 102 US: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2021–2026 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Availability of funding for research to offer growth opportunities in the Canadian market
TABLE 103 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2020 (USD MILLION)
TABLE 104 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021–2026 (USD MILLION)
TABLE 105 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION)
TABLE 106 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 107 CANADA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 108 CANADA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 109 CANADA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION)
TABLE 110 CANADA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION)
TABLE 111 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION)
TABLE 112 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION)
TABLE 113 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2020 (USD MILLION)
TABLE 114 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2021–2026 (USD MILLION)
10.3 EUROPE
TABLE 115 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 116 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
TABLE 117 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2020 (USD MILLION)
TABLE 118 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021–2026 (USD MILLION)
TABLE 119 EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 120 EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 121 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION)
TABLE 122 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 123 EUROPE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 124 EUROPE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 125 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION)
TABLE 126 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION)
TABLE 127 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION)
TABLE 128 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION)
TABLE 129 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2020 (USD MILLION)
TABLE 130 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2021–2026 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Prevalence of chronic medical conditions such as cancer and diabetes will support market growth in Germany
TABLE 131 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2020 (USD MILLION)
TABLE 132 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021–2026 (USD MILLION)
TABLE 133 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION)
TABLE 134 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 135 GERMANY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 136 GERMANY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 137 GERMANY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION)
TABLE 138 GERMANY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION)
TABLE 139 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION)
TABLE 140 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION)
TABLE 141 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2020 (USD MILLION)
TABLE 142 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2021–2026 (USD MILLION)
10.3.2 ITALY
10.3.2.1 Rising incidences of cancer to drive demand for TDM in Italy
TABLE 143 ITALY: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
TABLE 144 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2020 (USD MILLION)
TABLE 145 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021–2026 (USD MILLION)
TABLE 146 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION)
TABLE 147 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 148 ITALY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 149 ITALY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 150 ITALY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION)
TABLE 151 ITALY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION)
TABLE 152 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION)
TABLE 153 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION)
TABLE 154 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2020 (USD MILLION)
TABLE 155 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2021–2026 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Awareness regarding the benefits of TDM to accelerate its demand across various therapeutic applications
TABLE 156 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2020 (USD MILLION)
TABLE 157 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021–2026 (USD MILLION)
TABLE 158 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION)
TABLE 159 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 160 FRANCE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 161 FRANCE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 162 FRANCE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION)
TABLE 163 FRANCE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION)
TABLE 164 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION)
TABLE 165 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION)
TABLE 166 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2020 (USD MILLION)
TABLE 167 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2021–2026 (USD MILLION)
10.3.4 SPAIN
10.3.4.1 Adoption of technologically advanced immunoassays has boosted the market in Spain
TABLE 168 SPAIN: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
TABLE 169 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2020 (USD MILLION)
TABLE 170 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021–2026 (USD MILLION)
TABLE 171 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION)
TABLE 172 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 173 SPAIN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 174 SPAIN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 175 SPAIN: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION)
TABLE 176 SPAIN: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION)
TABLE 177 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION)
TABLE 178 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION)
TABLE 179 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2020 (USD MILLION)
TABLE 180 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2021–2026 (USD MILLION)
10.3.5 UK
10.3.5.1 Increasing cases of chronic diseases to drive the growth of the TDM market
TABLE 181 UK: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2020 (USD MILLION)
TABLE 182 UK: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021–2026 (USD MILLION)
TABLE 183 UK: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION)
TABLE 184 UK: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 185 UK: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 186 UK: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 187 UK: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION)
TABLE 188 UK: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION)
TABLE 189 UK: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION)
TABLE 190 UK: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION)
TABLE 191 UK: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2020 (USD MILLION)
TABLE 192 UK: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2021–2026 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 193 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2020 (USD MILLION)
TABLE 194 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021–2026 (USD MILLION)
TABLE 195 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION)
TABLE 196 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 197 ROE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 198 ROE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 199 ROE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION)
TABLE 200 ROE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION)
TABLE 201 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION)
TABLE 202 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION)
TABLE 203 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2020 (USD MILLION)
TABLE 204 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2021–2026 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 30 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT
TABLE 205 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 206 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
TABLE 207 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2020 (USD MILLION)
TABLE 208 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021–2026 (USD MILLION)
TABLE 209 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 210 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 211 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION)
TABLE 212 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 213 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 214 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 215 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION)
TABLE 216 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION)
TABLE 217 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION)
TABLE 218 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION)
TABLE 219 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2020 (USD MILLION)
TABLE 220 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2021–2026 (USD MILLION)
10.4.1 JAPAN
10.4.1.1 Japan holds the largest share of the APAC market for therapeutic drug monitoring
TABLE 221 JAPAN: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
TABLE 222 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2020 (USD MILLION)
TABLE 223 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021–2026 (USD MILLION)
TABLE 224 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION)
TABLE 225 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 226 JAPAN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 227 JAPAN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 228 JAPAN: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION)
TABLE 229 JAPAN: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION)
TABLE 230 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION)
TABLE 231 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION)
TABLE 232 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2020 (USD MILLION)
TABLE 233 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2021–2026 (USD MILLION)
10.4.2 CHINA
10.4.2.1 Rising number of organ transplants in the country will drive the growth of the TDM market
TABLE 234 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2020 (USD MILLION)
TABLE 235 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021–2026 (USD MILLION)
TABLE 236 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION)
TABLE 237 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 238 CHINA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 239 CHINA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 240 CHINA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION)
TABLE 241 CHINA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION)
TABLE 242 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION)
TABLE 243 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION)
TABLE 244 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2020 (USD MILLION)
TABLE 245 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2021–2026 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Rising incidence of cancer to propel market growth
TABLE 246 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2020 (USD MILLION)
TABLE 247 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021–2026 (USD MILLION)
TABLE 248 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION)
TABLE 249 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 250 INDIA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 251 INDIA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 252 INDIA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION)
TABLE 253 INDIA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION)
TABLE 254 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION)
TABLE 255 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION)
TABLE 256 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2020 (USD MILLION)
TABLE 257 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2021–2026 (USD MILLION)
10.4.4 ROAPAC
TABLE 258 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2020 (USD MILLION)
TABLE 259 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021–2026 (USD MILLION)
TABLE 260 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION)
TABLE 261 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 262 ROAPAC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 263 ROAPAC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 264 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION)
TABLE 265 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION)
TABLE 266 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION)
TABLE 267 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION)
TABLE 268 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2020 (USD MILLION)
TABLE 269 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2021–2026 (USD MILLION)
10.5 REST OF THE WORLD
10.5.1 ROW ACCOUNTS FOR THE SMALLEST SHARE OF THE OVERALL MARKET BUT IS EXPECTED TO SEE HIGH GROWTH
TABLE 270 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2020 (USD MILLION)
TABLE 271 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021–2026 (USD MILLION)
TABLE 272 ROW: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 273 ROW: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 274 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION)
TABLE 275 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
TABLE 276 ROW: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION)
TABLE 277 ROW: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 278 ROW: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION)
TABLE 279 ROW: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION)
TABLE 280 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION)
TABLE 281 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION)
TABLE 282 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2020 (USD MILLION)
TABLE 283 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2021–2026 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. - 208)
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
TABLE 284 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN THE THERAPEUTIC DRUG MONITORING MARKET
11.3 MARKET SHARE ANALYSIS
TABLE 285 THERAPEUTIC DRUG MONITORING MARKET: DEGREE OF COMPETITION
11.4 COMPANY EVALUATION QUADRANT
11.4.1 STARS
11.4.2 EMERGING LEADERS
11.4.3 PERVASIVE PLAYERS
11.4.4 PARTICIPANTS
FIGURE 31 COMPANY EVALUATION QUADRANT: THERAPEUTIC DRUG MONITORING MARKET
11.5 COMPANY EVALUATION QUADRANT FOR SMES/START-UPS
11.5.1 PROGRESSIVE COMPANIES
11.5.2 STARTING BLOCKS
11.5.3 RESPONSIVE COMPANIES
11.5.4 DYNAMIC COMPANIES
FIGURE 32 COMPANY EVALUATION MATRIX FOR SMES/START-UPS: THERAPEUTIC DRUG MONITORING MARKET
11.6 COMPANY FOOTPRINT ANALYSIS
TABLE 286 COMPANY FOOTPRINT
TABLE 287 COMPANY REGIONAL FOOTPRINT
TABLE 288 COMPANY PRODUCT FOOTPRINT
11.7 COMPETITIVE SCENARIO
11.7.1 PRODUCT APPROVALS
TABLE 289 KEY PRODUCT APPROVALS
11.7.2 PRODUCT LAUNCHES
TABLE 290 KEY PRODUCT LAUNCHES
11.7.3 AGREEMENTS
TABLE 291 KEY AGREEMENTS
11.7.4 ACQUISITIONS
TABLE 292 KEY ACQUISITIONS
11.7.5 OTHER DEVELOPMENTS
TABLE 293 KEY EXPANSIONS
12 COMPANY PROFILES (Page No. - 221)
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 ABBOTT
TABLE 294 ABBOTT: BUSINESS OVERVIEW
FIGURE 33 ABBOTT: COMPANY SNAPSHOT (2020)
12.1.2 THERMO FISHER SCIENTIFIC
TABLE 295 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 34 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020)
12.1.3 F. HOFFMANN-LA ROCHE
TABLE 296 F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW
FIGURE 35 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2020)
12.1.4 SIEMENS HEALTHINEERS AG
TABLE 297 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
FIGURE 36 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2020)
12.1.5 DANAHER CORPORATION
TABLE 298 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
12.1.6 BIO-RAD LABORATORIES
TABLE 299 BIO-RAD LABORATORIES: BUSINESS OVERVIEW
FIGURE 38 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2020)
12.1.7 BIOMÉRIEUX SA
TABLE 300 BIOMÉRIEUX SA: BUSINESS OVERVIEW
FIGURE 39 BIOMÉRIEUX SA.: COMPANY SNAPSHOT (2020)
12.1.8 THERADIAG SA.
TABLE 301 THERADIAG SA.: BUSINESS OVERVIEW
FIGURE 40 THERADIAG SA.: COMPANY SNAPSHOT (2020)
12.1.9 GRIFOLS S.A.
TABLE 302 GRIFOLS S.A.: BUSINESS OVERVIEW
FIGURE 41 GRIFOLS S.A.: COMPANY SNAPSHOT (2020)
12.1.10 EXAGEN INC.
TABLE 303 EXAGEN INC.: BUSINESS OVERVIEW
FIGURE 42 EXAGEN INC.: COMPANY SNAPSHOT (2020)
12.1.11 R-BIOPHARM AG
TABLE 304 R-BIOPHARM AG: BUSINESS OVERVIEW
12.1.12 APDIA GROUP
TABLE 305 APDIA: BUSINESS OVERVIEW
12.1.13 BIOTEZ BERLIN BUCH GMBH
TABLE 306 BIOTEZ BERLIN BUCH GMBH: BUSINESS OVERVIEW
12.1.14 EAGLE BIOSCIENCES, INC.
TABLE 307 EAGLE BIOSCIENCES, INC.: BUSINESS OVERVIEW
12.1.15 JASEM LABORATORY SYSTEMS AND SOLUTIONS
TABLE 308 JASEM LABORATORY SYSTEMS AND SOLUTIONS: BUSINESS OVERVIEW
12.1.16 AALTO SCIENTIFIC, LTD.
TABLE 309 AALTO SCIENTIFIC, LTD: BUSINESS OVERVIEW
12.1.17 IMMUNDIAGNOSTIK AG.
TABLE 310 IMMUNDIAGNOSTIK AG: BUSINESS OVERVIEW
12.1.18 UTAK
TABLE 311 UTAK: BUSINESS OVERVIEW
12.1.19 SEKISUI MEDICAL CO., LTD.
TABLE 312 SEKISUI MEDICAL CO., LTD.: BUSINESS OVERVIEW
12.1.20 RANDOX LABORATORIES LTD.
TABLE 313 RANDOX LABORATORIES LTD.: BUSINESS OVERVIEW
12.1.21 DIASYSTEM SCANDINAVIA AB
TABLE 314 DIASYSTEM SCANDINAVIA AB: BUSINESS OVERVIEW
12.1.22 CAMBRIDGE LIFE SCIENCES LIMITED
TABLE 315 CAMBRIDGE LIFE SCIENCES LIMITED: BUSINESS OVERVIEW
12.1.23 ARK DIAGNOSTICS, INC.
TABLE 316 ARK DIAGNOSTICS, INC.: BUSINESS OVERVIEW
12.1.24 HROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH
TABLE 317 CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH: BUSINESS OVERVIEW
12.1.25 BÜHLMANN LABORATORIES
TABLE 318 BÜHLMANN LABORATORIES: BUSINESS OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 291)
13.1 INSIGHTS FROM INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 AVAILABLE CUSTOMIZATIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS
The study involved four major activities in estimating the current size of the Therapeutic Drug Monitoring market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
Extensive primary research was conducted after acquiring knowledge about the global market scenario through secondary research. Primary interviews were conducted from both the demand (heads of private labs, Diagnostics and hospitals, Scientists, Researchers) and supply sides (Therapeutic Drug Monitoring manufacturers and distributors).
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the Therapeutic Drug Monitoring market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and markets have been identified through extensive secondary research
- The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Data Triangulation
After arriving at the overall market size-using the market size estimation processes-the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the Therapeutic Drug Monitoring industry.
Report Objectives
- To define, describe, and forecast the global Therapeutic Drug Monitoring market based on product, and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the Therapeutic Drug Monitoring market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Product Analysis:
- Product matrix, which gives a detailed comparison of the product portfolios of each company
Geographic Analysis:
- Further breakdown of the European Therapeutic Drug Monitoring market into specific countries.
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Therapeutic Drug Monitoring Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Therapeutic Drug Monitoring Market